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ABSTRACT 
p53 acts as the single most vital gene in cancer as a single mutation that can lead to 
tumorgenesis.  p53 function has been further diversified by the discovery of various isoforms 
of p53. p53 (also known as protein 53 or tumor protein 53), is a tumor suppressor protein that 
is encoded by the TP53 gene in case of humans. p53 is very vital in multicellular organisms, 
where it maintains the cell cycle and thus act as a tumor suppressor that is associated in 
suppressing cancer. p53 has been described as "the guardian of the genome" because of its 
role in conserving stability by preventing genome mutation. Integrin-associated signalling is a 
critical in signalling network in mammalian cells. Several molecules are concerned in this 
signalling network like the RTK, Ras, Src-family kinase,   Notch, Wnt, and Raft/caveolae-
mediated signalling pathways are associated to integrin signalling. Integrin signalling is also 
related with direct involvement of tumor formation, angiogenesis, metastasis, lipid rafts and 
attachment to distant tissues are largely coupled with integrin signalling. Recent data has 
indicated that integrin expression and its functions are tightly synchronized by epigenetic 
mechanisms. Alterations in these epigenetic regulation patterns are regularly associated with 
the development of various diseases, including cancer. Here we are trying to correlate the 
impact of p53 & β1 integrin in leukemia cell. 
 
Keywords: Cell cycle, p53, βintegrin, cancer, oncogenes. 
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INTRODUCTION 
              A gene is a unit of heredity that specify all the proteins.  Genes hold the information 
to build and retain an organism's cells and pass genetic traits to offspring. Gene is a locatable 
region of genomic sequence, associated to a part of inheritance, which is linked with 
regulatory, transcribed and functional sequence region. Any disorder in the gene sequences 
causes various kinds of diseases. The body's system is self-possessed of billions of cells 
which frequently grows and divide as long as the growth and continuation of the body takes 
place. Our body regularly replace the worn-out cells with new cells to keep on healthy. To do 
this, cells must enter a regulatory pathway known as cell cycle. The cell cycle has included 
pedals for how fast, and for how long a cell will go on dividing. Such organize mechanism is 
called the homeostatic mechanism or Traffic controllers of the cell. Such a mechanism 
controlled by signals that decide when to keep on in or departure the cell cycle. The tumor 
suppressor genes and proto-oncogenes make up the go and stop signals of this mechanism, 
respectively. Tumor suppressor genes code for proteins to "stop" signals that tell a cell to go 
away the cell cycle and stop dividing. The proto-oncogenes code for the "go" signals to stay 
in the cell cycle and keep on to separate.  
           Heritable deregulation of genes and disorder in cell cycle regulation is the main cause 
of cancer.  Oncogenes and tumor suppressor genes play a central role in development of 
cancer. P53 is one of the important transcription factors that maintain cell cycle. p53 (protein 
53), is a tumor suppressor protein that in humans is encoded by the TP53 gene. p53 is vital in 
multicellular organisms, where it regulates the cell cycle and is involved in preventing 
cancer. p53 has many mechanisms of anticancer function, and plays a vital role in genomic 
stability, inhibition of angiogenesis and apoptosis.  
           Mutations of p53 in tumors are also suspected to induce resistance to cancer 
chemotherapy (Boudreau et al., 1995). One response to genotoxic stress involves the p53 
tumor suppressor gene product (Brown and Wouters, 1999; Tada et al., 1998). p53 
accumulates after DNA damage and controls cellular proliferation predominantly as it act as 
a transcription factor. Downstream genes contribute to tumor suppression either by cell arrest, 
time to repair the damage and avoid genetic instability. 
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Another important group of cell adhesion receptors are integrins that mediate 
organization among a cell and the tissues adjoining it which may be other cells or the extra 
cellular matrix. Integrin plays an important role in cell signaling and thus regulate cellular 
shape, motility, and the cell cycle. Classically, receptors notify a cell of the molecules in its 
environment and the cell responds. Integrins perform both outside-in and inside-out mode of 
signaling. Therefore, they transduce in order from the ECM to the cell as well as reveal the 
status of the cell to the outside and allow rapid and flexible response to changes in the 
environment. Integrins are essential for numerous cellular physiologies and functions, from 
embryonic development throughout to immunological defense connecting various 
immunoglobulin superfamily members.   There are several types of integrin, and many cells 
have several types on their surface.  
Integrins work along other proteins such as   immunoglobulin super family cell 
adhesion molecules, cadherins, selectins and syndecans to mediate cell–cell and cell–matrix 
interaction and communication. Integrins attach cell surface and ECM components such as 
fibronectin, vitronectin, collagen, and laminin. This signalling is also allied with direct 
involment of lipid raft. . Several studies have shown that the integrin signalling mechanism is 
altered in cancer cells and facilitates cancer progression by causing tumor formation, 
metastasis, desmoplasia, angiogenesis, inflammation and lymph angiogenesis. (White et al., 
2004; Leung, 2010). 
 P53 and β1Integrin are epigenetically regulated with each other. Chemo sensitivity-
related genes such as integrin β1 and p53 are optional to relate to cancer prognosis. 
Activation of intracellular signals include tyrosine phosphorylation of focal adhesion kinase 
(FAK), that binds to the integrin β1 cytoplasmic realm and is one of the molecule that 
coclusters with β1 integrins aggregate by noninhibitory antiintegrin antibodies. Integrin β 1 
and p53 are painstaking to be part of the same signal pathway that induces programmed cell 
death. Mutant p53 Promotes b1-Integrin that cause  Cell Motility and Invasion (Patricia et al., 
2009). It had been pragmatic that α5β1 integrin antagonists constantly inhibit the 
chemotherapy-induced p53-dependent premature senescence by modulating the p53 pathway 
to relieve chemotherapy-induced apoptosis. It has been verified that p53 can inhibit the 
survival function of integrins by inducing the caspase-dependent cleavage and inactivation of 
the serine/threonine kinase AKT/PKB. 
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REVIEW OF LITERATURE 
Cell cycle: 
                Cell cycle is a tightly regulated process in which a cell grows, number of DNA will 
be doubled, and divides into two identical daughter cells. The cell cycle consists of four 
coordinated processes: cell growth, DNA replication, distribution of the parent chromosomes 
to daughter cells and cell division. The cell cycle is a complex process consists of four 
discrete phases. As the basic the cell cycle is divided   into two parts:  interphase and mitosis.  
In interphase the cell grows, accumulates its nutrients and duplicates its DNA. The 
chromosomes are condensed and distributed throughout the nucleus. This phase taken 95% 
part of the cell cycle. Mitosis is an important phase of cell cycle where separation of daughter 
chromosome occurs and this is followed by cytokinesis.  
                The timing of DNA synthesis divides the cell cycle into four phases: M, G1,S & 
G2.S phase is the period of synthesis of DNA where DNA replication occur. The cell grows 
throughout the interphase includes G1, S, G2. The cell divides into two identical daughter 
cell in the mitotic phase. There is another phase known as quiescent phase or G0 phase where 
the cells are metabolically active but stop its proliferation. 
 
Fig.1 [Phases Of Cell Cycle, cell and molecular biology,2011] 
           Heritable deregulation of genes and defect in cell cycle is the main cause of cancer. 
During carcinogenesis genes can become activated to enhance cell division or prevent cell 
death. These genes are known as oncogenes. In the other way they can become inactivated so 
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that they no longer are available to apply the brakes to this process. These genes are known as 
tumor suppressor genes.  
Genes can become inactivated by three pathways 
1. a gene can be mutated so that its function becomes disabled 
2. a gene can be completely lost and thus not be available to work appropriately 
3. a gene ,which has not been  lost or mutated can be switched off in a heritable fashion by 
epigenetic change 
Oncogene 
Oncogene is a gene that has the potential to cause cancer and are usually mutated or 
expressed at high levels in tumor cells. Most normal cells undergo a programmed form of 
death (apoptosis). Mutations in another gene, or environmental factors, such as viral infection 
triggers oncogene to cause cancer. Normally cancer drugs target to  those proteins encoded 
by oncogenes.  
Tumor supressor gene 
A tumor suppressor gene is also called as an anti-oncogene, by Knudson, is a gene that 
protects the cell from developing cancerous properties. When the gene is mutated to cause a 
loss  in its function, then the cell can progress to cancer, typically in combination with other 
genetic changes. Some of the epithets used for tumor suppressor genes are the gatekeeper, 
Caretaker and Landscaper (Boudreau N etal., 1995). 
       They are known as the gatekeepers because their loss of function is rate-limiting for a 
particular step in multi-stage tumorigenesis as well as they act directly to prevent tumor 
formation , and finally, restoring gatekeeper function to tumor cells suppress neoplasia.  
Kinzler and Vogelstein subsequently qualified the gatekeeper definition of tumor suppressor 
genes to include all direct inhibitors of cell growth such as inducing programmed cell death, 
promoting differentiation or suppressing proliferation,.  
                Mutations in tumor suppressor gene are recessive that indicate that, as long as the 
cell has one normal allele, tumor suppression continues. Whereas Oncogenes, behave as 
dominants that is one mutant, or overly-active, allele can incline the cell to tumor formation. 
p53 belongs to an sole protein family which include three members; p53, p63 (Schmale 
5 
 
H,etal) and p73 (Kaghad M etal). These proteins are structurally and functionally linked to 
each other, p53 seem to have evolved in higher organisms to prevent tumor development, 
while p63 and p73 have clear roles in normal developmental biology (Irwin MS etal). 
P53: 
p53 (also known as protein 53), is one of the chief tumor suppressor protein that is encoded 
by the TP53 gene in humans. p53 is crucial in multicellular organisms, where it regulates and 
maintain the cell cycle and thus functions as a tumor suppressor that helps in 
suppressing cancer.  p53 has several role in  anticancer function, and plays a  critical role in 
cell death, inhibition of angiogenesis, and genomic stability. In anti-cancer role, p53 works 
through several mechanisms: 
 It can activate the DNA repair proteins when the DNA has continued to damage. 
 It can stimulate growth arrest by stop the cell cycle at the G1/S regulation point on 
DNA damage recognition (if it holds the cell here for long enough, the DNA repair 
proteins will have time to fix the damage and the cell will be allowed to continue the 
cell cycle). 
 It can initiate apoptosis,  if DNA damage proves to be irreparable 
 
Fig.2 [Role of p53 in cell cycle, Thierry Soussi, 2007] 
p53 protein is a stress activated transcription factor therefore activated p53 can either induce 
or repress transcription of many target genes. Proteins encoded by these target genes are 
involved in the regulation of diverse biological functions including angiogenesis, cell 
senescence, DNA repair, apoptosis, cell cycle,cell migration (Oren,M., 2003). 
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Diverse stressors, including DNA damage, oncogene activation, hypoxia/anoxia, 
ribonucleotide depletion and loss of support, stabilize the p53 protein and enhance its 
activity(Vousden,K.H. et al.,2002). The p53 protein possesses the typical structural domains 
of a transcription factor as well as several unique domain. This feature include the DNA 
binding domain, basic regulatory region, the proline – rich domain, transactivation domain. 
Central DNA binding domain mediates sequence specific binding to chromatin (Wang, Y.et 
al.,1993). MDM2 is a nuclear phosphoprotein, which possesses numerous important 
functional domains, including the p53-binding domain, a central acidic region along with a 
C4 zinc finger, and a C-terminal RING domain, which confers MDM2’s E3 ligase activity. 
 Mutation of the p53 in tumors is also suspected to induce resistance to cancer 
chemotherapy (Boudreau et al., 1995). One response to genotoxic stress involves the p53 
tumor suppressor gene product (Brown and Wouters, 1999; Tada et al., 1998). The p53 
accumulates after the DNA damage and also controls cellular proliferation predominantly 
through its activity as transcription factor. Expression of downstream genes contributes to the 
tumor suppression either by activating cell arrest; possibly to give the cell time, to repair the 
damage and evade genetic instability. 
Since p53 gene has been found to be mutated in more than 50% of human cancers, it 
has fascinated the interest of numerous researchers. Ability of p53 for several biological 
functions can be attributed to its ability to act as a sequence-specific transcription factor to 
control expression of over one hundred different targets, and thus to transform various 
cellular processes like apoptosis, cell cycle arrest, DNA repair, etc. p53 protein with its 
specific C- and N-terminal structures is severely modulated by several biological processes 
like  acetylation, phosphorylation and ubiquitination through which it effectively regulates 
the cell growth and cell death.  
p53 mutations may lead either to loss or change of p53 binding activity to its 
downstream targets and may thus induce abnormal cell proliferation, with subsequent 
malignant cellular transformation. Based on p53’s critical role in carcinogenesis, scientists 
have developed several effective strategies for treating cancer by enhancing function of wild-
type p53 or increasing p53 stability. (Journal of Cancer Molecules) 
                p53 was previously viewed as an oncogene, but during these past several decades it 
has come to be understood as a tumor suppressor gene. Till date, many p53 family 
transcriptional targets have been recognized for having the ability to adapt various cellular 
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processes including growth arrest, apoptosis, senescence, differentiation, and DNA repair. In 
fact, it is evident that this small 53- kDa tumor suppressor is a molecular node at the 
crossroads of an widespread and complex network of stress response pathways.      
Deregulation of p53 has vast influence on carcinogenesis because mt p53 can provoke an 
increased epigenetic instability of tumor cells, that facilitate and accelerated the evolution of 
the tumor. The function of p53 is, currently a major challenge in p53 research field, and such 
knowledge may eventually afford to novel targets and approaches to therapeutic manipulation 
of the p53 pathway in the healing of cancer. Challenge in the future will be to use the 
knowledge of p53 and to develop more extremely effective strategy and novel drugs for 
cancer prevention and treatment with less side effects. (Journal of Cancer Molecules) 
 
Fig.3 [Regulation of passage from G1S, referred from Lehninger text book. ] 
 
Integrin: 
Integrins are super family of cell adhesion receptors that will bind to extracellular 
matrix, soluble ligands and cell surface ligand. These are the transmembrane αβ heterodimers 
and at least 18 α and eight β subunits are present in humans, which produced 24 
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heterodimers. Members of this family are seen in mammals, chicken and zebrafish, as well as 
sponges. The nematode (Caenorhabditis elegans)  have two α and one β subunits and the 
fruitfly( Drosophila melanogaster)  have five α and one β unit that produce  five integrins 
heterodimers. α and β subunits have distinct domain structures.Due to different extracellular 
domains integrin produce different types of ligand-binding  heterodimer.  
                 The  common integrin –binding motif of integrin sequence was arginine-glycine-
aspartic acid (RGD), but for a particular protein ligands individual integrins are specific. 
Integrin ligands are Immunologically important that the members of immunoglobulin 
superfamily, intercellular adhesion molecules (ICAMs) present on the antigen-presenting 
cells and inflamed endothelium. Due to binding of ligand to the ECM  integrins transduce 
signals into the cell interior; they can also accept intracellular signals that regulate their 
ligand-binding affinity. (Takada et al).  
                   There are various types of integrins present in eukaryotic vertebrates. Beta-1 
interact with many alpha integrin chains and form heterodimers. Gene knockout of integrins 
in mice are not always lethal, which proves that during embryonic development, one integrin 
may substitute its function for another in order to permit survival. Altered expression of β1 
integrins has been linked to both tumor progression (Friedrichs et al., 1995) and tumor 
suppression (Zutter et al., 1995) in different human malignancies. 
TABLE1: Heterodimers of β1 Integrin. 
Name Synonyms Distribution Ligands 
α1β1  Many Collagens, laminins 
α2β1  Many Collagens, laminins 
α4β1 VLA-4 Hematopoietic cells Fibronectin, VCAM-1 
α5β1 fibronectin 
receptor 
Widespread fibronectin and proteinases 
α6β1 laminin 
receptor 
Widespread matrix macromolecules laminins 
αLβ2 LFA-1 T-lymphocytes  ICAM-1, ICAM-2 
αMβ2 Mac-1, CR3 Neutrophils and monocytes Serum proteins, ICAM-1 
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αIIbβ3 Vibronectin  Platelets fibrinogen, fibronectin 
αVβ3 vitronectin 
receptor 
activated endothelial cells, 
melanoma, glioblastoma 
vitronectin, fibronectin, 
fibrinogen  osteopontin Cyr61 
αVβ5  widespread, esp. fibroblasts, 
epithelial cells 
vitronectin and adenovirus 
αVβ6  proliferating epithelia, esp. lung 
and liver 
fibronectin; TGFβ1+3 
α6β4  Epithelial cells Laminin  
               
             Integrin-associated signaling is a fundamental signalling network in mammalian 
cells. Actin filaments are normally regarded as a critical determinant of cell adhesion, 
spreading, and migration (M. Vicente-Manzanares etal). Thousands of molecules are 
implicated in this signalling network. Major signalling pathways that are related to integrin 
signalling are the RTK, Wnt, Src- kinase family, Ras, Notch, and Raft family. 
 Integrin signalling and lipid raft are linked directly and regulating various signalling 
mechanism. Induced Tumor formation, metastasis, angiogenesis and attachment to distant 
tissues are largely associated with integrin signalling. Recent data has indicated that integrin 
expression and its functions are tightly regulated by epigenetic mechanisms (modifications of 
DNA and histones). Disorder in these epigenetic regulation patterns are frequently linked 
with the progress of various diseases, including cancer (Patra, S. K.,2008). 
Integrins may activate or inhibit a signal through various means, including lipid raft–
caveolin, RTK, Akt, Ras signaling  pathway and regulate cell  migration, 
angiogenesis,survival, and programmed cell death. Integrin expression is tacitly controlled 
via various signaling pathways, which are interlinked with activated integrin signaling. These 
signals maintain a tightly regulated cycle like   PKCε, PKCα, PKD1,VCAM- 1, VCAM-4, 
VCAM-8,Arf6,EGFR etc. Molecules frequently regulate integrin signaling, but their 
regulation pattern is changed in a cancer cell. 
 Cell cycling,Integrin pathway regulation, internalization  are tightly regulated and 
maintained  processes in a normal cell. 
 Due to p53 mutation tumorigenesis occure which cause overexpression of RAB411A, 
RAB4A, VCAM, etc.  These molecules are epigenetically modified and under goes 
endosomal recycling, or exocytosis of cancer activator molecules.So tumor-suppressing 
receptor molecules are repressed. This deregulation occured by metastasis, angiogenesis,  
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invasion and tumor cell growth. 
               Integrin expression depends on the epigenetic marks present in the same gene. 
Change in epigenetic mark are the guides to irregular integrin expression in a cancer cell. On 
the extra part, downstream integrin signals adapted the epigenetic blueprint of different 
cancer-associated genes and express physiological abnormalities. Throughout tumorigenesis, 
the entire signaling network and epigenetic marks are deregulated. However, these alterations 
and allied mechanisms are not still known, and we invite extra investigations regarding these 
web and expect new developments down the above-mentioned avenue of inquiry. 
Deciphering integrin signaling and epigenetic regulation in extra detail will contribute to the 
understanding of a variety of pathological states including cancer and will significantly aid in 
the realization of the intrinsic robustness of cellular homeostasis. 
 
              Cell adhesion, spreading on collagen are vital processes for development and wound 
healing in mammals are mediated by β1 integrins as well as the actin and intermediate 
filament cytoskeletons. Mechanisms by which these separate cytoskeletal system relate and 
regulate β1 integrins and cell spreading are very poorly defined. It has been previously 
reported that the actin crosslinking protein filamin A binds to the intermediate filament 
protein vimentin and these two proteins co-regulate in cell spreading.  
 
            Imaging of fixed and live cell preparations showed that phosphorylated vimentin is 
translocated to the cell membrane during spreading. Knockdown of filamin A inhibited cell 
spreading and the phosphorylation and re-distribution of vimentin. Knockdown of filamin A 
and/or vimentin reduced the cell surface expression and activation of β1 integrins, as 
indicated by immunoblotting of plasma membrane-associated proteins and shear force assays. 
In vitro pull-down assays using filamin A mutants showed that both vimentin and protein 
kinase Cɛ bind to repeats 1–8 of filamin A. Reconstitution of filamin-A-deficient cells with 
full-length filamin A or filamin A repeats 1–8 restored cell spreading, vimentin 
phosphorylation,  and the cell surface expression of β1 integrins. We conclude that the 
binding of filamin A to vimentin and protein kinase Cε is an essential regulatory step for the 
trafficking and activation of β1 integrins and cell spreading on collagen (Hugh Kim,et 
al.,2010) 
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 CSC's behaviors are constantly affected by external signals from their niche, 
including neighboring stromal, immune. Extracellular as well as paracrine effects are 
mediated commonly from cell-surface ligand receptor systems. Accumulating facts have 
demonstrated that cancer cells and CSC functions hinge on major receptor-mediated 
pathways. For example, receptor tyrosine kinases (RTK) family mediates the effects of 
multiple oncogenic growth factor pathways, among which the EGFR (epidermal growth 
factor receptor) is one of the best characterized in cancers, including prostate cancer. 
Malignant cancer cells frequently have increased EGFR signalling as a result of either 
amplified EGFR copy number or reciprocal crosstalk with TGF-β. The signal that is initiated 
by RTKs is transduced and amplified through downstream molecule cascades, such as Ras-
MAPK, Ras-Raf-MEKERK- Elk, and the pro-survival AKT/phosphoinositide 3-
hydroxykinase pathway (Patra S.K et al). 
 
Recent research in cancer biology, including prostate cancer has provided support for 
the cancer stem-cell hypothesis (Blum et al. 2009). Two important components of this 
hypothesis are that tumors originate in stem or progenitor cells as a result of deregulation of 
the normally tightly regulated process of self-renewal. Cellular subcomponent that retains key 
stem-cell properties including self-renewal that activate tumorigenesis and differentiation 
cause cellular heterogeneity. Stem-cell technology is more advanced method that led to the 
identification of stem cells in normal and malignant tissues. 
The study of these stem cells has helped to elucidate the origin of the molecular 
complexity of human cancers. The cancer stem-cell hypothesis has important implications for 
early detection, prevention, and treatment of prostate and other cancers like colon cancer. 
Especially, both hereditary and periodic prostate cancers may develop through deregulation 
of stem-cell self replenishment pathways. These peculiar stem cells may make available 
targets for the development of cancer prevention strategies. Furthermore, because prostate 
cancer stem cells may be highly resistant to chemotherapy and radiation, the development of 
more successful therapies for this disease may require the effective targeting of this cell 
population (Patra S.K et al). 
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P53 and β1Integrin: Epigenetic regulation 
 P53 and β1Integrin are epigenetically regulated with each other. Chemo sensitivity-
related genes such as integrin β1 and p53 are optional to relate to cancer prognosis. 
Activation of intracellular signals include tyrosine phosphorylation of focal adhesion kinase 
(FAK),that binds to the integrin β1 cytoplasmic realm and is one of the molecules that 
coclusters with β1 integrins aggregate by noninhibitory antiintegrin antibodies. Integrin β 1 
and p53 are painstaking to be part of the same signal pathway that induces cells in apoptosis. 
It had been pragmatic that α5β1 integrin antagonists constantly inhibit the chemotherapy-
induced p53-dependent premature senescence by modulating the p53 pathway to ease 
chemotherapy-induced apoptosis. 
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OBJECTIVES 
 
   1. Isolation of mRNA for semi quantitative study of gene expression. 
            2. Semi quantitative study of p53 and β1 integrin in blood cell and leukemia cell. 
            3. Impact of p53 and β1 integrin Expression in Blood cell and leukemia cell.  
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4. MATERIALS AND METHODS 
4.1 Collection of Samples: 
            Blood was collected as the normal tissue from the local CWS Hospital, Rourkela, Odisha, 
stored in ice and instantly processed for better RNA extraction.  Cancer tissue (Leukemia) was 
collected from National Medical College, Kolkata and stored in RNA later (Sigma) at –200C until the 
extraction of RNA. 
4.2 Extraction of Total RNA: 
Total RNA was extracted from blood (normal) and leukemia blood using GeneJET
TM 
RNA Purification Kit (Fermentas), Manual RNA Extraction techniques and Trizol method. 
4.2.1 Extraction from Blood by RNA Purification Kit: 
The collected blood was centrifuged at 3000 rpm for 15 mins at 4° C. The supernatant 
containing the serum was separated from the pellet which contains the blood cells. The pellet 
was resuspended in 600 μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-
mercaptoethanol/1ml of Lysis Buffer) and vortexed to mix thoroughly. 450 μl of ethanol (96-
100%) was mixed with the solution. Then, about 700 μl of the lysate was transferred to a 
GeneJET
TM 
RNA Purification Column inserted in a collection tube and centrifuged at 12000 
rpm for 1 min at 4° C. The flow-through was discarded and the column was placed into a new 
2 ml RNase-free microcentrifuge tube to which 700 μl of Wash Buffer 1(supplemented with 
250 μl of ethanol for every 1ml Wash buffer 1) was added and centrifuged for 1 min at 12000 
rpm. The flow-through was discarded and 600 μl of Wash Buffer 2 (supplemented with 850 
μl of ethanol for each 0.5 μl Wash buffer 2) was added to the given column. It was 
centrifuged at 12000 rpm for 1 min at 4° C. The flow-through was  discarded. Centrifugation 
was done at 12000 rpm for 1 min at 4 ° C by adding 250 μl of Wash buffer 2. The flow-
through was discarded and the column was placed to a sterile 1.5ml RNase-free eppendorf 
tube. 100 μl of nuclease-free water was added to the column and centrifuged for 1 min at 
12000 rpm to elute RNA. The RNA was stored at - 20° C for further use or immediately 
processed for cDNA synthesis. 
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4.2.2. m RNA Extraction by Manual Method: 
Chemical Reagents and Buffer:-  
Chloroform isoamyl alcohol - 49:1,Ethanol,Isopropanol,PBS,Sodium Acetate, Solution D 
(Denaturating Solutions) ,Guanidium Thiocyanate,  Sodium Citrate, Sodium Lawryl 
Sarcosinate, β Mercaptoethanol  
Procedure:- 
             The collected blood sample was centrifuged at 3000rpm for 10 min (room 
temperature). PBS was added and centrifuged (room temperature).The pellet was collected 
and 2ml of solution D was added for 106 cells. The cells were homogenized for 15 to 30 sec 
in room temperature. 0.1ml of 2M sodium acetate (pH-4.0), 1ml of phenol and 0.2ml of 
chloroform: isoamylalcohol per milliliter of solution D was added. It was mixed thoroughly 
by inversion. The homogenate was gently vortexed vigorously for 10 sec; the tube was 
incubated for 15 minutes on ice to permit complete dissociation of nucleoprotein complex. 
The tube was centrifuged at 9000rpm for 20 min at 4
◦
C. The extracted RNA was collected in 
the upper aqueous solution. An equal volume of isopropanol was added to the extracted RNA 
and the solution was mixed and the RNA was allowed to precipitate for 1min at -20
◦
C. RNA 
was collected by centrifugation at 9000rpm at 4
◦
C for 30 min. Isopropanol was carefully 
decanted and the RNA pellet was dissolved in 0.3ml Solution D for every 1ml of solution 
used in early step.The solution was transfered to a microfuge tube, it was vortexed well and 
the RNA was precipitated with 1 volume of isopropanol for1 hour or more at -20
◦
C. The 
precipitate RNA was collected by centrifuge at maximum speed for 10mins at 4
◦
C.The pellet 
was washed twice with 75% ethanol. It was again centrifuged and allowed to dry completely. 
 
4.2.3 For Extraction from Cancer tissue:  
           About 30 mg of frozen cancer tissue was taken and thoroughly homogenized using 
Lysis buffer. The homogenized tissue was transferred into a sterile 2 ml microcentrifuge tube 
containing 300 μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-
mercaptoethanol/1ml of Lysis Buffer). The mixture was thoroughly mixed by vortexing for 
10 sec. The next steps of extraction were same as that followed in the previous protocol for 
blood RNA extraction. 
 
16 
 
4.3 Quantitative Estimation of RNA Concentration by Spectrophotometric Analysis: 
The concentration of the extracted total RNA from both blood and cancer tissue was 
quantified by measuring the absorbance at 260 nm in a spectrophotometer (ELICO, BL 200 
Bio Spectrophotometer, double beam) and calculated by using the formula as given below: 
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
4.4 Quantitative Estimation of RNA Concentration by Denaturing Gel   
Electrophoresis: 
 
The extracted RNA from both blood and cancer tissue was run on a denaturing 
agarose gel and the quantity of RNA estimated from the band intensity. For denaturation gel 
(40 ml), 0.6 g agarose (Sigma), 28.8 ml dH2O (Sigma), 7.2 ml formaldehyde (Sigma), 4 ml 
10X MOPS buffer were mixed properly. About 2 μl (2μg) of the total RNA was mixed with 
18 μl 1X Reaction Buffer (2μl of 10X MOPS Buffer, 10 μl formamide (Sigma), 4 μl 
formaldehyde, 2 μl 0.2 mg/ml Etbr (Sigma)) and incubated at 55 °C for 1 hr. It was then 
cooled on ice and loaded in the wells of the denaturing gel. 
4.5. First strand cDNA synthesis: 
Total RNA (4 g) from both blood and cancer tissue were used for first strand cDNA 
synthesis by reverse transcription using RevertAid
TM 
First Strand cDNA Synthesis Kit 
(Fermentas) in a thermocycler (Biorad). The RNA samples were incubated with 1 l of oligo 
(dT)  primers (100 μM, 0.2 μg/μl) and 12 μl of nuclease-free water at 65 C for 5 min. The 
reaction was cooled on ice to allow the primers to anneal to the RNA, then spin down and 
placed on ice again after which the following components were added to the reaction in 
order; 4 l of 5X Reaction Buffer, 1 l of RibolockTM RNase inhibitor (20 U/l), 2 l of 10 
mM dNTPs and 1.0 L of RevertAidTM M-MuLV-Reverse Transcriptase (200 U/l). The 
reagents were gently mixed and incubated for 1 hr at 42C and then at 70C for 5 min 
terminated the reaction and the synthesized cDNA was stored at –20 0 C for further use. 
4.6. Gene-specific PCR for amplification of the desired gene: 
4.6.1 Selection of Primers: 
           A set of specific forward and reverse primers for the amplification of the desired gene 
under study was selected from published papers (Boldrup L.,Christophe J.B.et al 2007). The 
cDNA of both the blood and cancer tissue synthesized were used as the template for the 
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specific primers. The constitutively expressed housekeeping gene, β-actin was taken as a 
positive control to ensure high quality. The primer sequences are mentioned in Table 1:  
Table 2. Table showing the sequence of the forward and backward primers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                      
 
 
4.6.2 PCR conditions: 
 
                       The PCR sample mixtures (25 μl), contained 17 μl of dH2O (Sigma), 2.5 μl of 1X 
PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, Sigma), 0.5 
μl each of the forward and reverse primers (0.2 μM, Sigma) p53 and 0.5 μl Taq DNA-
polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was added. PCR amplifications of 
p53 and β1 integrin were performed in a thermal cycler by initial denaturation at94° C for 1 
min, followed by 30 cycles of denaturation at 94° C for 1 min, annealing at 94 ° C for 30 
secs, and extension at 60° C for 45 secs, followed by final extension step at 72° C for 5 mins. 
4.7 Agarose Gel Electrophoresis of the PCR products: 
The generated PCR products were analyzed by electrophoresis on 1.2% agarose gel. 
Agarose gel was prepared with 1X TAE (Tris Acetate EDTA, Sigma) buffer. Before casting 
ethidium bromide (1μl of 10mg/ml stock in 30 ml) was added to the gel. 15 μl of sample 
PRIMER TYPE    SEQUENCE 
p53   Forward   5‘-
GTCACTGCCATGGAGGAGCCGCA-
3‘  
    
                                                           Reverse  5‘-  GTCACTGCCATGGAGGAGCCGCA-3‘  
  Forward   5′ CAAATTGTGGGTGGTGCACA 
3′ 
β1 integrin              Reverse  5′ TGGAGGGCAACCCTTCTTT-3’ 
    
β-ACTIN   Forward   5‘ TCTACAATGAGCTGCGTGTG 
3‘  
    
               Reverse  5‘ TCTCCTTCTGCATCCTGTC 3‘  
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(PCR product) was loaded to each well along with 3 μl 1 X loading dye. 5 μl of DNA marker 
(100 bp- 3 kb, Sigma). The gel was run in TAE buffer at 100 volt for 40 minutes. 
4.8 Analysis of the Relative Expression level of the different genes:  
The relative levels of expression of each gene were analyzed by taking the band 
intensity using Quantity One software, Biorad. The ratios of desired genes/β-actin product 
were subsequently calculated after subtraction of the background pixel intensity for each gene 
of interest and used to assess the differences in expression levels between normal and 
leukemia blood.  
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RESULTS AND DISCUSSION 
 
For Normal (Blood) Tissue 
Tissue  Concentration (µg/ml)  Purity (260/280) nm  
Normal  tissue (Blood)  476.8  1.82  
Leukemia cell  44.7  1.18  
                
        Table.3: Spectrophotometer results of total RNA from blood tissue 
 
 
 
                                                            
     [Total RNA from normal                                                            [Total RNA  from leukemia 
blood human blood in 1% agarose gel]                                                       in 1 % agarose gel]                                      
Fig.4 Gel picture showing total RNA extracted from normal and leukemia cell. 
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  Expression of p53 from normal blood                                                    
                                                                                                                                      
                                   
Expression of p53 from leukemia blood             
 
                                    
Expression of Beta integrin from normal human  
 
                                    
Expression of Beta integrin from leukemia patient  
Fig.5 Gel picture showing specific gene expression run on agarose gel. 
 p53 and p300:               
           P300 is a histone actyltransferase and has twin action on p53. It has been previously 
reported that it might either stabilize or help in the breakdown of p53. Expression of both 
p300 and p53 in the leukemia blood sample suggests that p300 acts as a stabilizer to stabilize 
the p53 by Acetylation. Stable p53 is expected to promote apoptosis and prevent tumor 
formation.  
 
 
 
150bp 
150bp 
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p53 and β1 integrin: 
          It has been reported that α5β1 integrin antagonists consistently inhibit the 
chemotherapy-induced p53-dependent premature senescence by modulating the p53 pathway 
to facilitate chemotherapy-induced apoptosis. It has been established that p53 can inhibit the 
survival role of integrins by inducing
 
the caspase-dependent cleavage and inactivation of the 
serine/threonine
 
kinase AKT/PKB. 
 
p53 and HDAC:- 
 
p53 in combination with HDAC results in the repression of surviving which is an inhibitor of 
apoptosis gene either by  methylation dependent or independent mechanism. p53 and HDAC 
expression  in absence of DNMT1 might lead to repression of surviving in methylation 
independent mechanism. Such type of pro-apoptotic environment will not lead to tumor 
formation. Thus it may be assumed that p53β expression changes its interaction pattern with 
HDAC, inactivating surviving repression and so promoting tumor. 
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CONCLUSION 
 
 p53 being a tumor suppressor gene is anticipated to be not expressed by cancer cells. 
However the leukemia cells show the expression of p53. This means that some other 
mutation or aberration is also involved in cancer formation which can be hooked in to p53 
expression. Moreover interactions of p53 with different cancer related genes show that, p53 
influences such interactions, usually showing abnormal behavior of tumor suppressor gene. 
Integrin expression is tacitly controlled via varied signaling pathways, which are interlinked 
with activated integrin signaling. These signals maintain a tightly regulated web. Integrin 
trafficking, internalization, and recycling are tightly regulated processes in an exceedingly 
normal cell. p53 is down-regulated in case of leukemia blood in comparison to normal blood 
sample. β1 integrin was up-regulated in case of leukemia blood  as compared  to normal 
blood sample.  
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